A randomized phase iii adjuvant study in high-risk cervical cancer: Simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A noggo-ago intergroup study

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2259-2264

  Sehouli, J ^a   Runnebaum, I B ^b   Fotopoulou, C ^a   Blohmer, U ^c   Belau, A ^d   Leber, H ^e   Hanker, L C ^f   Hartmann, W ^g   Richter, R ^a   Keyver paik, M D ^h   Oberhoff, C ⁱ   Heinrich, G ^j   Du bois, A ^k   Olbrich, C ^l   Simon, E ^m   Friese, K ⁿ   Kimmig, R ^o   Boehmer, D ^a   Lichtenegger, W ^a   Kuemmel, S ^p  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c Sankt Gertrauden Krankenhaus   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e Klinik fuer Strahlentherapie   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g Klinikum Frankfurt Oder GmbH   (Germany)

^h UNIVERSITY HOSPITAL BONN   (Germany)

ⁱ Department of Gynecology   (Germany)

^j Gyn oncological Praxis   (Germany)

^k Horst Schmidt Klinik   (Germany)

^l DRK KLINIKEN BERLIN WESTEND   (Germany)

^m Kreiskrankenhaus Torgau Johann Kentmann GmbH   (Germany)

ⁿ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^o UNIVERSITY HOSPITAL ESSEN   (Germany)

^p KLINIKEN ESSEN MITTE   (Germany)

more..

Author keywords

Cervical cancer; Morbidity; Percutaneous radiation; Radiochemotherapy; Sequential treatment; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ABDOMINAL CRAMP; ADJUVANT CHEMORADIOTHERAPY; ADOLESCENT; ADULT; AGED; ALLERGY; ALOPECIA; ANOREXIA; ARTERY EMBOLISM; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; DYSURIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HYPERTENSION; INCONTINENCE; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DERMATITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VOMITING;

EID: 84865546034     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr628     Document Type: Article

References (15)

1. American Cancer Society. Cancer Facts & Figures 2008. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf (21 May 2008, date last accessed).
2. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med 2007; 45: 93.
3. Peters WA, III, Liu PY, Barrett RJ, II et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18(8): 1606-1613.
4. Mabuchi S, Morishige K, Isohashi F et al. Postoperative concurrent nedaplatinbased chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecol Oncol 2009; 115(3): 482-487.
5. Green J, Kirwan J, Tierney J et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005; (3): CD002225.
6. Moore DH, Blessing JA, McQuellon RP et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004; 22: 3113-3119.
7. Mori T, Hosokawa K, Sawada M et al. Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer: long-term results. Int J Gynecol Cancer 2010; 20(4): 611-616.
8. Saito I, Kitagawa R, Fukuda H et al. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol 2010; 40(1): 90-93.
9. Takano M, Kikuchi Y, Kita T et al. Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin. Onkologie 2009; 32: 10595-597.
10. Kitagawa R, Katsumata N, Yamanaka Y et al. Phase II trial of paclitaxel and carboplatin in patients with recurrent or metastatic cervical carcinoma. Proc Am Soc Clin Oncol 2004; 23: 5048.
11. National Cancer Institute. Common Toxicity Criteria, Version 3. 0. http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
13. Long HJ, III, Bundy BN, Grendys EC, Jr et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4626-4633.
14. Rosenthal DI, Liu L, Lee JH et al. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck 2002; 24(2): 115.
15. Pectasides D, Fountzilas G, Papaxoinis G et al. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer. Int J Gynecol Cancer 2009; 194:777-781.